

DAFTAR PUSTAKA

- Al-temimi, S. M. A. (2011) 'Correlation between BCL2 protein expression and clinicopathological parameters of colorectal carcinoma', 14(2), pp. 206–213.
- Aletra C, Ravazoula P, Scopa C, Kounelis S, Sotiropoulou G, Kourounis G, et al. (2000) 'Expression of bcl-2 and bax in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix.' *Eur J Gynaecol Oncol*;21:494-8
- American Cancer Society (2019) 'Cervical Cancer Causes, Risk Factors, and Prevention Risk Factors', American Cancer Society, p. 2.
- Andrews, G, (2010) 'Buku Ajar Kesehatan Reproduksi Wanita' Jakarta: EGC.
- Andrijono and Indriyatmi, W. (2013) *Infeksi Human Papiloma Virus*. Jakarta: Fakultas Kedokteran Universitas Indonesia.
- Arbyn, M., Castellsague, X., Sanjose, S. de, Bruni, L., Saraiya, M., and Bray, F. (2011) 'Worldwide burden of cervical cancer in 2008', *Annals of Oncology*, 22(12), pp. 2675–2686. doi: 10.1093/annonc/mdr015.
- Badan Pengembangan dan Pembinaan Bahasa. (2016). *KBBI Daring*. Jakarta: Kementerian Pendidikan dan Kebudayaan Republik Indonesia
- Bhatla, N., Berek, J. S., Fredes, M. C., Denny, L. A., et al. (2019) 'Revised FIGO staging for carcinoma of the cervix uteri', *International Journal of Gynecology and Obstetrics*, 145(1), pp. 129–135. doi: 10.1002/ijgo.12749.
- Byun, S. J., Kim, J.H., Oh, Y.K., Cho, C.H., (2013) 'A comparison of outcomes between concurrent chemoradiotherapy and radiotherapy alone in cancer of the uterine cervix: A single institutional experience', *European Journal of Gynaecological Oncology*, 34(5), pp. 402–408. doi: 10.1016/j.ijrobp.2012.07.1148.
- Cancer Registry Himpunan Onkologi Ginekologi Indonesia (2021)
- Cibula, D., Raspollini, M.R., Planchamp, F., Centeno, C., et al. (2023) 'ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023*', *International Journal of Gynecological Cancer*, 33(5), pp. 649–666. doi: 10.1136/ijgc-2023-004429.
- Colombo, N., Carinelli, S., Colombo, A., Marini, C., Rollo, D., & Sessa, C., (2012) 'Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up', *Annals of Oncology*, 23(SUPPL. 7), pp. vii27–vii32. doi: 10.1093/annonc/mds268.
- Dahlan, S.M. (2009) *'Statistik untuk Kedokteran dan Kesehatan'* Edisi 4. Jakarta. Salemba Medika
- Dai, H., Meng, W. and Kaufmann, S. (2016) 'BCL2 Family, Mitochondrial Apoptosis, and Beyond', *Cancer Translational Medicine*, 2(1), p. 7. doi: 10.4103/2395-3977.177558.

- Dash, P., (2009). 'Apoptosis. Basic medical sciences', St.George's University of London, 1,pp.1–6. Available at: <http://www.ppgorgsistem.ics.ufba.br/arquivos/fatima/Apoptosis.pdf>.
- Di Saia, P.J., and Creasman, W. (2012) Clinical Gynecologic Oncology. 8th edn. China: Elsevier.
- Dimitrakakis, C., Kymionis, G., Diakomanolis, E., Papaspyrou, I., *et al.* (2000) 'The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions', *Gynecologic Oncology*, 77(1), pp. 129–136. doi: 10.1006/gyno.1999.5715.
- Dwivedi, R., Chandra, S., Mehrotra, D., Raj, V., Pandey, R. (2020) 'Predicting transition from oral pre-malignancy to malignancy via Bcl-2 immuno-expression: Evidence and lacunae', *Journal of Oral Biology and Craniofacial Research*, 10(4), pp. 397–403. doi: 10.1016/j.jobcr.2020.07.003.
- Elmore, S. (2015) 'Apoptosis: A Review of Programmed Cell Death', *Toxicologic Pathology*, 35(4), pp. 495–516. doi: 10.1080/01926230701320337.
- ESGO (2017) 'Cervical Cancer', *The Lancet*, 328(8517), p. 1226. doi: 10.1016/S0140-6736(86)92243-9.
- Garrey, S. (2014) 'Cervical Cancer in Uganda', Pulitzer Center on Crisis Reporting. Available at: <http://pulitzercenter.org/projects/sub-saharan-africa-uganda-female-reproductive-health-cervical-cancer-HPV>.
- Ghavami, S., Hashemi, M., Ande, S.R., Yeganeh, B., Xiao, W., Eshragi, M., Bus, C.J., Kadkhoda, K., Wiechec, E., Halayko, A.J., Los, M. (2009) 'Apoptosis and cancer : mutations within caspase genes', pp. 497–510. doi: 10.1136/jmg.2009.066944.
- Hanahan, D. and Weinberg, R. A. (2011) 'Hallmarks of cancer: The next generation', *Cell*, 144(5), pp. 646–674. doi: 10.1016/j.cell.2011.02.013.
- Hansen, B. T., Campbell, S. and Nygård, M. (2018) 'Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: A registry-based study in Norway', *BMJ Open*, 8(2), pp. 1–9. doi: 10.1136/bmjopen-2017-019005.
- Herzog, T. J. and Monk, B. J. (2007) 'Reducing the burden of glandular carcinomas of the uterine cervix', *American Journal of Obstetrics and Gynecology*, 197(6), pp. 566–571. doi: 10.1016/j.ajog.2007.08.055.
- Hoffman, B., Schorge, J., Bradshaw, K., Halvorson, L., Schaffer, J., & Corton, M. (2012) *Williams Gynecology*, The McGraw-Hill Companies.
- Hoots, B. E., Palefsky, J.M., Pimenta, J.M., & Smith, J.S., (2009) 'Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions', *International Journal of Cancer*, 124(10), pp. 2375–2383. doi: 10.1002/ijc.24215.
- Hoste, G., Vossaert, K. and Poppe, W. A. J. (2013) 'The Clinical Role of HPV Testing in Primary and Secondary Cervical Cancer Screening', *Obstetrics and Gynecology International*, 2013, pp. 1–7. doi: 10.1155/2013/610373.

- International Federation of Gynecology and Obstetrics (2018) 'FIGO Cancer Report 2018'. *International Journal of Gynecology & Obstetrics*, 143(2)
- International Federation of Gynecology and Obstetrics (2021) 'FIGO Cancer Report 2021'. *International Journal of Gynecology & Obstetrics*, 143(2)
- Kamaraddi, S., Nayak, A., Honnappa, S., & Swarup, A. (2016) 'Expression of Bcl-2 Marker in Premalignant Lesions of Cervical Cancer', *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, 5(4), pp. 965–969. doi: 10.36106/8216341.
- Kasamatsu, T., Onda, T., Sawada, M., Kato, T., & Ikeda, S. (2009) 'Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation', *Gynecologic Oncology*, 114(1), pp. 69–74. doi: 10.1016/j.ygyno.2009.03.026.
- Katsumata, N., Yoshikawa, H., Kobayashi, H., Saito, T., Kuzuya, K., Nakanishi, T., Yasugi, T., Yaegashi, N., Yokota, H., Kodama, S., Muzunoe, T., Hiura, M., Kasamatsu, T., Shibata, T., & Kamura, T. (2013) 'Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: A Japan Clinical Oncology Group trial (JCOG 0102)', *British Journal of Cancer*, 108(10), pp. 1957–1963. doi: 10.1038/bjc.2013.179.
- Koff, J. L., Ramachandiran, S. and Bernal-Mizrachi, L. (2015) 'A time to kill: Targeting apoptosis in cancer', *International Journal of Molecular Sciences*, 16(2), pp. 2942–2955. doi: 10.3390/ijms16022942.
- Kumar, V., Abbas, A., Aster, J., Ham, M., Saraswati, M. (2015) 'Buku Ajar Patologi Robbins', Elsevier.
- Kurman, R.J., Ronnet, B.M, Sherman, M.E, Wilkinson, E.J., (2010) 'Tumors of the Cervix, Vagina, and Vulva' American Registry of Pathology, 13(4), doi.org/10.55418/9781933477114
- Lee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., *et al.* (2022) 'Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer', 12(10), pp. 2372–2391. doi: 10.1158/2159-8290.CD-21-1026.Modulation.
- Letai, A. (2017) 'Apoptosis and cancer', *Annual Review of Cancer Biology*, 1, pp. 275–294. doi: 10.1146/annurev-cancerbio-050216-121933.
- Limpens, M. (2018). *Kanker. PodoPost*, 31(2), 5–5. doi:10.1007/s12480-018-0030-x
- Lindstr, A. (2010) *Prognostic factors for squamous cell cervical cancer*, *Oncology*.
- Lourenço de Freitas, N., Deberaldini, M.G., Gomes, D., Pavan, A.R., (2021) 'Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus', *Frontiers in Cell and Developmental Biology*, 8(January). doi: 10.3389/fcell.2020.592868.
- Jose A. Fonseca., Mountinho., (2011) 'Smoking and cervical cancer' International Scholarly Research Network ISRN Obstetrics and Gynecology Volume 2011, Article ID 847684, 6 pages doi:10.5402/2011/847684

- Lv, Y., Wang, N., Liu, Y., Li, X., (2015) 'Tumor invasion depth is a useful pathologic assessment for predicting outcomes in cervical squamous cell carcinoma after neoadjuvant radiotherapy', *Diagnostic Pathology*, 10(1), pp. 1–9. doi: 10.1186/s13000-015-0426-6.
- Mabuchi, S., Okazawa, M., Kinose, Y., Matsuo, K. (2012) 'Comparison of the prognoses of figo stage i to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy', *International Journal of Gynecological Cancer*, 22(8), pp. 1389–1397. doi: 10.1097/IGC.0b013e31826b5d9b.
- Maniar, K.P., and Wei, J.J. (2017) 'Pathology of Cervical Carcinoma'. The Global Library of Women's Medicine. Clinical Guidance and resources. (ISSN: 1756-2228); DOI 10.3843/GLOWM.10230
- Mantovani, F. and Banks, L. (2001) 'The Human Papillomavirus E6 protein and its contribution to malignant progression', *Oncogene*, 20(54), pp. 7874–7887. doi: 10.1038/sj.onc.1204869.
- Marin, F., Plesca, M., Bordea, C.I., Moga, M.A., & Blidaru, A. (2014) 'Types of radical hysterectomies : From Thoma Ionescu and Wertheim to present day', *Journal of medicine and life*, 7(2), pp. 172–176.
- Martinez-Ruiz, G.U., Vazquez-Santillan, K., & Victoria-Acosta, G. (2015). 'Cervical cancer and apoptosis'. Available at: <https://www.semanticscholar.org/paper/Cervical-cancer-and-apoptosis-Martinez-Ruiz-VazquezSantillan/c2f2be75d24d8ddf86e989b3eca822c21806417a>
- Masood, A., Azmi, A. S. and Mohammad, R. M. (2011) 'Small molecule inhibitors of Bcl-2 family proteins for pancreatic cancer therapy', *Cancers*, 3(2), pp. 1527–1549. doi: 10.3390/cancers3021527.
- Matsuo, K., Mandelbaum, R.S., Machida, H., Purushotham, S., Grubbs, B.H., Roman, L.D., & Wright, J.D. (2018) 'Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix', *Journal of Gynecologic Oncology*, 29(6), pp. 1–12. doi: 10.3802/jgo.2018.29.e91.
- McIlwain, D. R., Berger, T. and Mak, T. W. (2013) 'Caspase functions in cell death and disease', *Cold Spring Harbor Perspectives in Biology*, 5(4), pp. 1–28. doi: 10.1101/cshperspect.a008656.
- Ministry of Health and Social Welfare (2011) 'National Cervical Cancer Prevention and Control Strategic Plan 2011-2015' Reproductive and Child Health Section.
- Morshed, K., Polz-Gruska, D., Szymanski, M., & Polz-Dacewicz, M. (2014) 'Human Papillomavirus (HPV) - Structure, epidemiology and pathogenesis', *Otolaryngologia Polska*, 68(5), pp. 213–219. doi: 10.1016/j.otpol.2014.06.001.
- NIH Publication (2017). 'Understanding cervical changes. A health guide for women'. National Cancer Institute Publication No. 17-5199 May 2017

- Okawa, Y., Hideshima, T., Ikeda, H., Raje, N., Vallet, S., Kiziltepe, T., Yasui, H., Enatsu, S., Pozzi, S., Breitkreutz, I., Cirstea, D., Santo, L., Richardson, P. & Anderson, K.C. (2008). 'Fatty acid synthase is a novel therapeutic target in multiple myeloma', *British Journal of Haematology*, 141(5), pp. 659–671. doi: 10.1111/j.1365-2141.2008.07114.x.
- Olsson, M. and Zhivotovsky, B. (2011) 'Caspases and cancer', *Cell Death and Differentiation*, 18(9), pp. 1441–1449. doi: 10.1038/cdd.2011.30.
- Panici, P. B., Scambia, G., Baiocchi, G., Greggi, S., Ragusa, G., Gallo, A., Conte, M., Battaglia, F., Laurelli, G., & Rabitti, C. (1991) 'Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival', *Cancer*, 67(2), pp. 372–379. doi: 10.1002/1097-0142(19910115)67:2<372::AID-CNCR2820670210>3.0.CO;2-5.
- Prakosa, T., Askandar, B. and Fauziah, D. (2013) 'Ekspresi p53 Mutan dan caspase 3 sebagai Faktor Prediksi terhadap Operabilitas Kanker Serviks IIB setelah Mendapat Kemoterapi Neoajuvan', *Indonesia Journal of Cancer*, 7(2), pp. 61–70.
- Putri, R. D. R. (2019) Hubungan antara ekspresi p53 mutan dan respon kemoterapi neoadjuvan pada kanker serviks stadium IB2 dan IIA2. Available at: <http://repositorio.unan.edu.ni/2986/1/5624.pdf>.
- Halaby, R. (2014) 'Novel Anticancer Agent for Chemoresistant Cancer Cells that are Caspase-3 Deficient.', *J Mol Biol & Mol Imaging.*, 1(3), p. 8.
- Riemer, A. B., Keskin, D.B., Zhang, G., Handley, M., Anderson, K.S., Brusic, V., Reinhold, B., & Reinherz, E.L. (2010) 'A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers', *Journal of Biological Chemistry*, 285(38), pp. 29608–29622. doi: 10.1074/jbc.M110.126722.
- Ruengwanichayakun, P. (2021) 'Histochemical scoring assessment (H-score)', *Asian Archives of Pathology*, 13(1), pp. 13–14.
- Rydzewska, L., Tierney, J., Vale, C.L., and Symonds, P.R. (2012) 'Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer', *Cochrane Database of Systematic Reviews*, 2012(12). doi: 10.1002/14651858.CD007406.pub3.
- Saikia, B. and Thakuria., T. (2021) 'Study of Expression of Bcl-2 Marker in Premalignant Lesions of Cervical Cancer', *International Journal of Scientific Research*, 5(4), pp. 46–47. doi: 10.36106/8216341.
- Senkomago, V., Duran, D., Loharikar, A., Hyde, B.T., Makowitz, L.E., Unger, E.R., & Saraiya, M. (2017) 'CDC activities for improving implementation of human papillomavirus vaccination, cervical cancer screening, and surveillance worldwide', *Emerging Infectious Diseases*, 23(December), pp. S101–S107. doi: 10.3201/eid2313.170603.

- Shi, X. J., Yu, B., Wang, J., Qi, P.P., Tang, K., Huang, X., & Liu, H.M. (2016) 'Structurally novel steroidal spirooxindole by241 potently inhibits tumor growth mainly through ROS-mediated mechanisms', *Scientific Reports*, 6(February), pp. 1–14. doi: 10.1038/srep31607.
- Shukla, S., Dass, J. and Pujani, M. (2014) 'P53 and bcl2 expression in malignant and premalignant lesions of uterine cervix and their correlation with human papilloma virus 16 and 18', *South Asian Journal of Cancer*, 3(1), pp. 48–53. doi: 10.4103/2278-330X.126524.
- Stoler, M., Bergeron, C., and Colgan, T.J. (2014) 'Squamous Cell Tumours and Precursors', *World Health Organization Classification of Tumours of Female Reproductive Organs*, 4(IARC Lyon, France), pp. 172–182.
- Sugiyama, T., Nishida, T., Nishio, S., Fujiyoshi, K., Okura, N., Yakushiji, M., Hiura, M., & Umesaki, N. (1999) 'Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer', *British Journal of Cancer*, 81(1), pp. 95–98. doi: 10.1038/sj.bjc.6690656.
- Sultana, H., Kigawa, J., Kanamori, Y., Itamochi, H., Oishi, T., Sato, S., Kamazawa, S., Ohwada, M., Suzuki, M., & Terakawa, N. (2003) 'Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer', *Annals of Oncology*, 14(2), pp. 214–219. doi: 10.1093/annonc/mdg071.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. doi: 10.3322/caac.21660.
- Tresnasari, K. (2018) Hubungan negatif antara ekspresi caspase -3 dengan beberapa faktor klinikopatologi pada karsinoma sel skuamosa invasif serviks uteri.
- Wentz, W. B. and Reagan, J. W. (1959) 'Survival in cervical cancer with respect to cell type', *Cancer*, 12(2), pp. 384–388. doi: 10.1002/1097-0142(195903/04)12:2<384::AID-CNCR2820120222>3.0.CO;2-C.
- Wentzensen, N. and Doeberitz, M. von K. (2007) 'Biomarkers in Cervical Cancer', *Disease Markers*, 23(4), pp. 315–330. doi: 10.1155/2007/678793.
- Xia, L. and Xue, X. Z. (2012) 'Immunohistochemical study of NF-κB p65, c-IAP2 and caspase-3 expression in cervical cancer', *Oncology Letters*, 3(4), pp. 839–844. doi: 10.3892/ol.2012.564.
- Yang, S., Kong, S., Lee, S., Lim, S., & Park, C. (2014) 'Human papillomavirus 18 as a poor prognostic factor in stage I-IIA cervical cancer following primary surgical treatment', 57(6), pp. 492–500.
- Zhou, X. L. and Wang, M. (2015) 'Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis', 14(4), pp. 17059–17067.